Aimmune’s Peanut Allergy Immunotherapy Brings Safety Concerns To US FDA Panel

 
• By Sue Sutter

Palforzia was associated with a higher rate of adverse events, systemic allergic reactions, eosinophilic esophagitis and epinephrine use in controlled clinical trials; Allergenic Products Advisory Committee will weigh approval for patients ages 4-17 years with confirmed peanut allergy diagnosis.

Peanut_Butter
Palforzia could be the first oral immunotherapy approved to reduce the incidence and severity of allergic reactions to peanuts. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers